Abstract
Chagas disease is a neglected tropical disease caused by the parasite Trypanosoma cruzi. Despite the efforts and distinct methodologies, the search of antigens for diagnosis, vaccine, and drug targets for the disease is still needed. The present study is aimed at identifying possible antigens that could be used for diagnosis, vaccine, and drugs targets against T. cruzi using reverse vaccinology and molecular docking. The genomes of 28 T. cruzi strains available in GenBank (NCBI) were used to obtain the genomic core. Then, subtractive genomics was carried out to identify nonhomologous genes to the host in the core. A total of 2630 conserved proteins in 28 strains of T. cruzi were predicted using OrthoFinder and Diamond software, in which 515 showed no homology to the human host. These proteins were evaluated for their subcellular localization, from which 214 are cytoplasmic and 117 are secreted or present in the plasma membrane. To identify the antigens for diagnosis and vaccine targets, we used the VaxiJen software, and 14 nonhomologous proteins were selected showing high binding efficiency with MHC I and MHC II with potential for in vitro and in vivo tests. When these 14 nonhomologous molecules were compared against other trypanosomatids, it was found that the retrotransposon hot spot (RHS) protein is specific only for T. cruzi parasite suggesting that it could be used for Chagas diagnosis. Such 14 proteins were analyzed using the IEDB software to predict their epitopes in both B and T lymphocytes. Furthermore, molecular docking analysis was performed using the software MHOLline. As a result, we identified 6 possible T. cruzi drug targets that could interact with 4 compounds already known as antiparasitic activities. These 14 protein targets, along with 6 potential drug candidates, can be further validated in future studies, in vivo, regarding Chagas disease.
Highlights
Chagas disease is a neglected tropical disease that affects around 8 million people worldwide, caused by the protozoanTrypanosoma cruzi [1]
We found 14 proteins that are likely to be presented as antigens, from which 6 are mucin-associated surface proteins (MASPs), 6 are hypothetical proteins from different parasite strains, 1 is GP63 surface protease, and the latter was identified as putative retrotransposon hot spot protein (Table 3)
It has been shown that changes in the repertoire of antigenic MASP peptides may contribute to the evasion of the host immune response during the acute phase of the disease [31]
Summary
Chagas disease is a neglected tropical disease that affects around 8 million people worldwide, caused by the protozoanTrypanosoma cruzi [1]. Clinical manifestations of the disease may vary from severe myocarditis and/or changes in the gastrointestinal system, presenting megaesophagus and/or megacolon, to an asymptomatic or undetermined form [2]. During these phases, individuals have a strong cellular and humoral immune response [3, 4]. Despite these cellular and humoral immune responses, there is no diagnostic antigen yet to characterize and identify each of these phases of the disease Still, it is not clear which mechanisms trigger the transition from asymptomatic to symptomatic but what is known are the factors involved in the etiopathogenesis that are related to the parasite strains, parasite load, infection phase, and the host immune response [5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
